BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bennabi D, Haffen E, Van Waes V. Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research. Front Psychiatry 2019;10:771. [PMID: 31780961 DOI: 10.3389/fpsyt.2019.00771] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Adamo D, Pecoraro G, Coppola N, Calabria E, Aria M, Mignogna M. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis 2021;27:1022-41. [PMID: 32790904 DOI: 10.1111/odi.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 McDonnell CW, Dunphy-Doherty F, Rouine J, Bianchi M, Upton N, Sokolowska E, Prenderville JA. The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression. Front Psychiatry 2020;11:599588. [PMID: 33551869 DOI: 10.3389/fpsyt.2020.599588] [Reference Citation Analysis]
3 Caruso G, Grasso M, Fidilio A, Torrisi SA, Musso N, Geraci F, Tropea MR, Privitera A, Tascedda F, Puzzo D, Salomone S, Drago F, Leggio GM, Caraci F. Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer's Disease. Front Pharmacol 2021;12:809541. [PMID: 35002742 DOI: 10.3389/fphar.2021.809541] [Reference Citation Analysis]
4 Segura-Garcia C, Rania M, Carbone EA, de Filippis R, Aloi M, Caroleo M, Grasso G, Calabrò G, Fazia G, Staltari FA, Falvo A, Pugliese V, Gaetano R, Steardo L Jr, De Fazio P. Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. Front Psychiatry 2021;12:635502. [PMID: 33815170 DOI: 10.3389/fpsyt.2021.635502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Alexander L, Young AH. Recent advances in the psychopharmacology of major depressive disorder. BJPsych advances. [DOI: 10.1192/bja.2022.14] [Reference Citation Analysis]
6 Yavi M, Henter ID, Park LT, Zarate C. Key considerations in the pharmacological management of treatment-resistant depression. Expert Opin Pharmacother 2021;:1-11. [PMID: 34252320 DOI: 10.1080/14656566.2021.1951225] [Reference Citation Analysis]
7 Adamo D, Calabria E, Coppola N, Pecoraro G, Mignogna MD. Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update. Ther Adv Psychopharmacol 2021;11:20451253211034320. [PMID: 34497709 DOI: 10.1177/20451253211034320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mortensen JK, Andersen G. Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance. Expert Opin Pharmacother 2021;22:1157-66. [PMID: 33530765 DOI: 10.1080/14656566.2021.1880566] [Reference Citation Analysis]
9 Siwek M, Gorostowicz A, Bosak M, Dudek D. Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy—Case Series. Front Pharmacol 2022;13:852042. [DOI: 10.3389/fphar.2022.852042] [Reference Citation Analysis]
10 Sagud M, Nikolac Perkovic M, Dvojkovic A, Jaksic N, Vuksan-Cusa B, Zivkovic M, Kusevic Z, Mihaljevic-Peles A, Pivac N. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram. Psychopharmacology (Berl) 2021;238:1575-84. [PMID: 33560444 DOI: 10.1007/s00213-021-05790-2] [Reference Citation Analysis]
11 Hrnjadovic A, Friedmann J, Barhebreus S, Allen PJ, Kocsis B. Effect of a 5-HT7 Receptor Antagonist on Reversal Learning in the Rat Attentional Set-Shifting Test. ACS Chem Neurosci 2021;12:42-8. [PMID: 33337152 DOI: 10.1021/acschemneuro.0c00554] [Reference Citation Analysis]
12 Emery S, Häberling I, Berger G, Baumgartner N, Strumberger M, Albermann M, Nalani K, Schmeck K, Erb S, Bachmann S, Wöckel L, Müller-Knapp U, Contin-Waldvogel B, Rhiner B, Walitza S, Hersberger M, Drechsler R. Verbal Memory Performance in Depressed Children and Adolescents: Associations with EPA but Not DHA and Depression Severity. Nutrients 2020;12:E3630. [PMID: 33255819 DOI: 10.3390/nu12123630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Danielak D. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients? Expert Opin Pharmacother 2021;22:1167-77. [PMID: 33650935 DOI: 10.1080/14656566.2021.1880567] [Reference Citation Analysis]
14 De Diego-Adeliño J, Crespo JM, Mora F, Neyra A, Iborra P, Gutiérrez-Rojas L, Salonia SF. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf 2021;:1-18. [PMID: 34964415 DOI: 10.1080/14740338.2022.2019705] [Reference Citation Analysis]
15 Chakrabarty T, McInerney SJ, Torres IJ, Frey BN, Milev RV, Müller DJ, Rotzinger S, Kennedy SH, Lam RW; CAN-BIND Investigator Team. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. CNS Drugs 2021;35:291-304. [PMID: 33683582 DOI: 10.1007/s40263-021-00793-1] [Reference Citation Analysis]